Drug intelligence / Profile preview

Tang Shen No. 2 Formula

Development stage: Unknown
Lead developer: China-Japan Friendship Hospital
Administration: Oral

Overview

Tang Shen No. 2 Formula (糖肾2号方) is a Traditional Chinese Medicine (TCM) herbal preparation developed by Beijing Shijitan Hospital for the treatment of early-stage type 2 diabetic nephropathy. It is specifically formulated to address TCM syndromes associated with diabetic kidney disease, such as Qi and Yin deficiency combined with blood stasis. The formula aims to reduce urinary albumin excretion, improve renal function, and slow the progression of kidney damage in diabetic patients. It is currently being evaluated in clinical research settings, including the trial ChiCTR2000040002, to validate its therapeutic efficacy and safety profile as a complementary or alternative therapy to standard diabetic care.

Other names: 糖肾2号方Tangshen No. 2 Prescription

Beyond the preview

Go deeper on Tang Shen No. 2 Formula.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tang Shen No. 2 Formula.

Explore the full profile